Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 14/20 | 0.73 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.68 |
| ▸ | CDK2 | P24941 | 3/20 | 0.68 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.68 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.68 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.68 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.68 |
| ▸ | PIM1 | P11309 | 6/20 | 0.66 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.64 |
| ▸ | CDK9 | P50750 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29436156 | 1.00 | DYRK1A (0.73) | DYRK1ACCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL15699138 | 0.88 | DYRK1A (0.76) | DYRK1APIM1 | |
| SCHEMBL102421 | 0.86 | DYRK1A (0.91) | DYRK1APIM1 | |
| SCHEMBL14653586 | 0.85 | DYRK1A (0.73) | DYRK1APIM1 | |
| SCHEMBL24333230 | 0.85 | DYRK1A (0.83) | DYRK1APIM1 | |
| SCHEMBL103472 | 0.85 | DYRK1A (0.69) | DYRK1ACCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL26745373 | 0.84 | DYRK1A (1.00) | DYRK1APIM1 | |
| SCHEMBL18356750 | 0.84 | DYRK1A (0.66) | DYRK1ACCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL13234228 | 0.84 | DYRK1A (0.69) | DYRK1ACCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL19987042 | 0.82 | PIM1 (0.76) | DYRK1APIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240124469-A1 | PIM KINASE INHIBITOR | HANGZHOU BIOSUN PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4289847-A1 | PIM KINASE INHIBITOR | Hangzhou Biosun Pharmaceutical Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230355617-A1 | SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3 | THE UNIVERSITY OF SUSSEX (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230355617-A1 | SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3 | THE UNIVERSITY OF SUSSEX (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230355617-A1 | SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3 | THE UNIVERSITY OF SUSSEX (GB) | 2023-11-09 | — | — | US | disclosed |
| EP-4210697-A1 | SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3 | The University of Sussex (GB) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022166860-A1 | PIM KINASE INHIBITOR | 杭州邦顺制药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| US-7750007-B2 | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors | SUPERGEN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750007-B2 | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors | SUPERGEN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008058126-A2 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007147646-A1 | OXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | CDK2, CDK1, MAP4K2 | DYRK1A 445/4885CCNA2 241/4885CDK2 1/4885 |
| US-20240124469-A1 | PIM KINASE INHIBITOR | PIM1, PIM2, PIM3 | DYRK1A 500/4885CCNA2 2209/4885CDK2 232/4885 |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 171/4885CCNA2 1165/4885CDK2 65/4885 |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 221/4885CCNA2 929/4885CDK2 17/4885 |
| US-20230355617-A1 | SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3 | LMTK3, LMTK2, LIMK1 | DYRK1A 332/4885CCNA2 2976/4885CDK2 215/4885 |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | DYRK1A 461/4885CCNA2 650/4885CDK2 26/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 171/4885CCNA2 1165/4885CDK2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.